Compare Sutro Biopharma, Inc. (STRO) vs Revolution Medicines, Inc. (RVMD) vs Incyte Corporation (INCY) vs Genmab A/S (GMAB) vs Exelixis, Inc. (EXEL) Stock

Genmab A/S (GMAB) offers the better valuation at 15.4x trailing P/E (23.2x forward), making it the more compelling value choice. Analysts rate Sutro Biopharma, Inc. (STRO) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 15.4x versus Exelixis, Inc. at 15.8x. On forward P/E, Exelixis, Inc. is actually cheaper at 13.3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Exelixis, Inc. wins at 0.26x versus Genmab A/S's 0.80x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Revolution Medicines, Inc. (RVMD) delivered a total return of +121.8%, compared to -16.2% for Genmab A/S (GMAB). A $10,000 investment in RVMD five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: EXEL returned +1110% versus STRO's +34.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.61β versus Sutro Biopharma, Inc.'s 1.22β — meaning STRO is approximately 99% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 5% for Sutro Biopharma, Inc. — giving it more financial flexibility in a downturn.

Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus -366.6% for Sutro Biopharma, Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37.6% versus -384.3% for STRO. At the gross margin level — before operating expenses — EXEL leads at 96.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Exelixis, Inc. (EXEL) is the more undervalued stock at a PEG of 0.26x versus Genmab A/S's 0.80x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Exelixis, Inc. (EXEL) trades at 13.3x forward P/E versus 23.2x for Genmab A/S — 9.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 37.6% to $40.50.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc. (EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63), +1110% 10Y return). Both have compounded well over 10 years (EXEL: +1110%, STRO: +34.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: STRO is a small-cap quality compounder stock; RVMD is a mid-cap quality compounder stock; INCY is a mid-cap deep-value stock; GMAB is a mid-cap deep-value stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.